Nov 12, 2024 7:00 am EST Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
Nov 7, 2024 7:00 am EST Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
Oct 8, 2024 7:00 am EDT Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Aug 12, 2024 7:00 am EDT Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
Jul 16, 2024 7:00 am EDT Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
Jul 9, 2024 7:00 am EDT Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Jun 24, 2024 4:01 pm EDT Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
